

3,4,4-Trichloro-2-nitro-1-propylsulfanyl-
1-(4-thiomorpholinyl)buta-1,3-diene

Cemil Ibis* and N. Gulsah Deniz

Istanbul University, Faculty of Engineering,
Department of Chemistry, 34320
Avcilar-Istanbul, Turkey

Correspondence e-mail: ibiscml@istanbul.edu.tr

In the title compound, $C_{11}H_{15}Cl_3N_2O_2S_2$, the thiomorpholine ring adopts a chair conformation and the butadiene has a conformation closer to *cisoid* than to *transoid*.

Received 16 October 2006

Accepted 28 October 2006

Key indicators

Single-crystal X-ray study


 $T = 294$ KMean $\sigma(C-C) = 0.008$ Å R factor = 0.075 wR factor = 0.134

Data-to-parameter ratio = 15.5

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

Comment

Thiomorpholine analogues have found applications in medicine and agriculture (Barbacyn *et al.*, 1996). Substituted thiomorpholino, morpholino and piperidino compounds enhanced the activity against Gram-positive bacteria, but reduced the activity against Gram-negative bacteria (Taguchi *et al.*, 1992). The aim of this study was to determine the conformation of the title compound, (I).



The structure of (I) contains the expected *N,S*-substituted butadienyl skeleton, an alkylsulfanyl chain and a thiomorpholine ring (Fig. 1). The butadiene has a conformation




Figure 1

The molecular structure of (I), showing the atom labelling. Displacement ellipsoids are drawn at the 30% probability level and H atoms are represented as small spheres of arbitrary radii.

closer to *cisoid* than to *transoid*, the C4—C3—C2—C1 torsion angle being $-64.3(3)^\circ$. The C—C bond lengths within the butadiene unit are similar to those in related compounds (Surange *et al.*, 1997; Ibis *et al.*, 2006). The thiomorpholine ring adopts a chair conformation, as shown by the puckering angles of $\varphi = 1(3)^\circ$ and $\theta = 10.2(4)^\circ$ (Cremer & Pople, 1975).

Experimental

The title compound, (I), was synthesized from 2-nitro-1,3,4,4-tetrachloro-1-(propylsulfanyl)-1,3-butadiene and thiomorpholine (Ibis & Deniz, 2006). Equimolar amounts of 2-nitro-1,3,4,4-tetrachloro-1-(propylsulfanyl)-1,3-butadiene (0.4 g, 1.28 mmol) and thiomorpholine (0.13 g, 1.28 mmol) were stirred in dichloromethane until completion of the reaction. Chloroform (50 ml) was added to the reaction mixture. The organic layer was separated, washed with water (4×30 ml) and dried with CaCl_2 or MgSO_4 . After the solvent had evaporated, the residue was purified by column chromatography on silica gel. Yellow crystals of (I) suitable for X-ray diffraction analysis were obtained by slow evaporation of an ethanol solution at room temperature (yield: 0.26 g, 54%; m.p. 424–426 K).

Crystal data

$\text{C}_{11}\text{H}_{15}\text{Cl}_3\text{N}_2\text{O}_2\text{S}_2$
 $M_r = 377.73$
 Monoclinic, $P2_1/n$
 $a = 11.3127(5) \text{ \AA}$
 $b = 9.1100(3) \text{ \AA}$
 $c = 16.3114(8) \text{ \AA}$
 $\beta = 102.803(2)^\circ$
 $V = 1639.24(12) \text{ \AA}^3$

$Z = 4$
 $D_x = 1.530 \text{ Mg m}^{-3}$
 Mo $K\alpha$ radiation
 $\mu = 0.81 \text{ mm}^{-1}$
 $T = 293.5 \text{ K}$
 Platelet, yellow
 $0.40 \times 0.20 \times 0.20 \text{ mm}$

Data collection

Rigaku R-AXIS RAPID S
 diffractometer
 ω scans
 Absorption correction: multi-scan
 (ABSCOR; Higashi, 1995)
 $T_{\min} = 0.820$, $T_{\max} = 0.852$

63776 measured reflections
 2824 independent reflections
 2824 reflections with $I > 2\sigma(I)$
 $R_{\text{int}} = 0.039$
 $\theta_{\text{max}} = 25.2^\circ$

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.075$
 $wR(F^2) = 0.134$
 $S = 1.48$
 2824 reflections
 182 parameters
 H-atom parameters constrained

$$w = 1/[\sigma^2(F_o^2) + (0.0165P)^2 + 2.4574P]$$

where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\text{max}} < 0.001$
 $\Delta\rho_{\text{max}} = 0.33 \text{ e \AA}^{-3}$
 $\Delta\rho_{\text{min}} = -0.25 \text{ e \AA}^{-3}$

All H atoms were positioned geometrically and treated as riding, with C—H = 0.93 (CH_3) or 0.97 \AA (CH_2), with $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{CH}_2)$ and $1.5U_{\text{eq}}(\text{CH}_3)$.

Data collection: *CrystalClear* (Rigaku/MSC, 2002); cell refinement: *CrystalClear*; data reduction: *CrystalStructure* (Rigaku/MSC, 2003); program(s) used to solve structure: *SIR92* (Altomare *et al.*, 1994); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEP-3* (Farrugia, 1997); software used to prepare material for publication: *SHELXL97*.

This work was supported by the Research Fund of the University of Istanbul.

References

- Altomare, A., Cascarano, G., Giacovazzo, C., Guagliardi, A., Burla, M., Polidori, G. & Camalli, M. (1994). *J. Appl. Cryst.* **27**, 435.
 Barbacyn, M. R., Hutchinson, D. K., Brickner, S. J., Cynamon, M. H., Kilburn, J. O., Klemens, S. P., Glickman, S. E., Grega, K. C., Hendges, S. K., Toops, D. S., Ford, C. W. & Zurenko, G. E. (1996). *J. Med. Chem.* **39**, 680–685.
 Cremer, D. & Pople, J. A. (1975). *J. Am. Chem. Soc.* **97**, 1354–1358.
 Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
 Higashi, T. (1995). *ABSCOR*. Rigaku Corporation, Tokyo, Japan.
 Ibis, C. & Deniz, N. G. (2006). In preparation.
 Ibis, C., Sayil, M. C. & Deniz, N. G. (2006). *Acta Cryst.* **E62**, o800–o801.
 Rigaku/MSC (2002). *CrystalClear*. Version 1.3.5. Rigaku/MS, The Woodlands, Texas, USA.
 Rigaku/MSC (2003). *CrystalStructure*. Version 3.5.1. Rigaku/MS, The Woodlands, Texas, USA.
 Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.
 Surange, S. S., Kumaran, G., Rajappa, S., Rajalakshmi, K. & Pattabhi, V. (1997). *Tetrahedron*, **53**, 8531–8540.
 Taguchi, M., Kondo, H., Inoue, Y., Kawahata, Y., Jinbo, Y., Sakamoto, F. & Tsukamoto, G. (1992). *J. Med. Chem.* **35**, 94–99.